Senate Committee Lambastes Industry Response To FDA Year 2000 Initiative
This article was originally published in The Gray Sheet
Executive Summary
The lukewarm response by medical device manufacturers to FDA's call for information related to year 2000 compliance could jeopardize the industry's Y2K "shield" from liability claims, Sen. Christopher Dodd (D-Conn.) warned at a July 23 hearing of the Senate Special Committee on the Year 2000 Problem.
You may also be interested in...
Device Industry Y2K Preparation Efforts Pay Off With Few Glitches
A handful of minor problems related to the year 2000 calendar conversion, reported primarily outside the U.S. since the turn of the century, has done little to detract from an overall perception that the device industry has sailed through the year change essentially unscathed.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.